Barium ( DrugBank: Barium )

3 diseases

ID	Disease name (Link within this page)	Number of trials
2	Amyotrophic lateral sclerosis	1
19	Lysosomal storage disease	1
98	Eosinophilic gastrointestinal disease	2

2. Amyotrophic lateral sclerosis

Clinical trials : 624 / Drugs : 611 - (DrugBank : 160) / Drug target genes : 172 - Drug target pathways : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04889898 (ClinicalTrials.gov)	January 1, 2022	7/5/2021	Remote Speech and Swallowing Assessment in ALS	Home Telemonitoring of Bulbar Function by Acoustic Measurement of Swallowing and Speech Sounds in ALS	Amyotrophic Lateral Sclerosis	Device: Digital recording of speech and swallow sounds using the Beiwe Digital Health App on a personal smartphone;Radiation: Modified Barium Swallow Study (MBSS);Behavioral: Speech Intelligibility Test (SIT);Behavioral: SIT Scoring	Milton S. Hershey Medical Center	Penn State University;Congressionally Directed Medical Research Programs	Recruiting	18 Years	N/A	All	170		United States

Clinical trials : 854 / Drugs : 716 - (DrugBank : 105) / Drug target genes : 70 - Drug target pathways : 191

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03952637 (ClinicalTrials.gov)	August 19, 2019	15/5/2019	A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	A Phase 1-2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	Lysosomal Diseases;Gangliosidosis;GM1	Biological: AAV9-GLB1;Drug: Rituximab;Drug: Sirolimus;Drug: Methylprednisolone;Drug: Prednisone;Diagnostic Test: Audiology assessmentwith ABR;Diagnostic Test: Bone density scan (DEXA;Diagnostic Test: Electrocardiogram (EKG);Diagnostic Test: Echocardiogram;Other: Electroencephalogram (EEG) awake andextended overnight;Diagnostic Test: Laboratory tests;Procedure: Lumbar puncture;Procedure: Brain MRI/MRS/fMRI;Behavioral: Neurocognitive testing;Other: Neurology exam;Behavioral: PICC line placement;Procedure: Skeletal survey;Procedure: Skin biopsy;Procedure: Speech and modified barium swallow study;Procedure: Ophthalmology exam	National Human Genome Research Institute (NHGRI)	Axovant Sciences, Inc.;Sio Gene Therapies (Sponsor)	Recruiting	6 Months	12 Months	All	45	Phase 1/Phase 2	United States

Clinical trials : 171 / Drugs : 184 - (DrugBank : 47) / Drug target genes : 42 - Drug target pathways : 141

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03290482 (ClinicalTrials.gov)	June 19, 2017	24/8/2017	Natural History of Eosinophilic Esophagitis	Natural History of Eosinophilic Esophagitis: A Longitudinal Follow-up Over 10 Years	Eosinophilic Esophagitis	Diagnostic Test: Barium Esophagram;Device: EsophaCap;Diagnostic Test: Physical Examination and Questionnaires	Mayo Clinic	NULL	Completed	18 Years	N/A	All	65		United States
2	NCT01865825 (ClinicalTrials.gov)	March 2013	23/5/2013	Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)?	PPI Responsive Esophageal Eosinophilia: GERD or Eosinophilic Esophagitis?	Erosive Esophagitis	Radiation: Esophageal Barium Xray	Mayo Clinic	NULL	Completed	18 Years	N/A	All	20	N/A	United States